Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables
- PMID: 18376330
Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables
Abstract
Aim: To compare patient's attitudes, demographic, clinical characteristics, psychopathology, insight and type of antipsychotic therapy in compliant and non-compliant outpatients with schizophrenia; to explore correlations between patient's attitudes and related variables.
Methods: A sample of 44 outpatients of both genders (> 60 years), with a diagnosis of ICD-10 Schizophrenia (F20) was included into the study. All the patients were on maintenance treatment with different classes of antipsychotics (oral, depot or both), for at least 6 months from the latest hospitalisation. The exclusion criteria were determined. The BPRS and the PANSS were used to assess psychopathology and insight (G12 item). The self-report questionnaire MARS was used to assess patient's attitudes.
Results: Compliant patients (N=37) showed the following significant differences compared to non-compliant patients (N=7): higher the MARS (p<0.001), lower the PANSS (Positive sub score) (p<0.01) G12 scores (p<0.01) (the Student t test) and percentage of patients with previous non-compliance (p<0.05) (chi2 test). Considerable correlation between the MARS and the BPRS (p<0.001), the PANSS (Positive, General psychopathology) (p<0.001; p<0.01), G12 scores (p<0.05) (negative) and current compliance (p<0.001) was also found (The Spearman's correlation).
Conclusions: Our results suggest that special attention should be paid to attitudes, severity of psychopathology, insight and history of non-compliance in compliance evaluation of outpatients with schizophrenia.
Similar articles
-
Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020. Clin Ther. 2008. PMID: 19167596
-
[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].Encephale. 2013 May;39 Suppl 1:S8-14. doi: 10.1016/j.encep.2012.03.005. Epub 2013 Mar 28. Encephale. 2013. PMID: 23541914 French.
-
Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy.Vojnosanit Pregl. 2013 Mar;70(3):267-73. doi: 10.2298/vsp1303267s. Vojnosanit Pregl. 2013. PMID: 23607237
-
Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.J Clin Psychiatry. 2003;64 Suppl 16:34-40. J Clin Psychiatry. 2003. PMID: 14680417 Review.
-
Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.Int J Clin Pract. 2007 Dec;61(12):1979-88. doi: 10.1111/j.1742-1241.2007.01431.x. Int J Clin Pract. 2007. PMID: 17997804 Review.
Cited by
-
Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.BMC Psychiatry. 2012 Aug 21;12:122. doi: 10.1186/1471-244X-12-122. BMC Psychiatry. 2012. PMID: 22909285 Free PMC article.
-
Patient perspectives on antipsychotic treatments and their association with clinical outcomes.Patient Prefer Adherence. 2010 Oct 5;4:369-77. doi: 10.2147/ppa.s12461. Patient Prefer Adherence. 2010. PMID: 21049089 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous